Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis

European Journal of Haematology
Philippe MoreauJesús F San-Miguel

Abstract

Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs). Managing AEs are important to ensure patients continue therapy long enough to receive the best clinical benefit. Data from the MM-002, MM-003, and MM-010 trials were pooled to further characterize the safety profile of pomalidomide plus low-dose dexamethasone and AE management. This analysis included 1088 patients who received ≥ 2 prior therapies, including lenalidomide and bortezomib, and progressed ≤ 60 days of last therapy. Patients received 28-day cycles of pomalidomide 4 mg/day on days 1-21 and low-dose dexamethasone 40 mg (20 mg if aged > 75 years) weekly until disease progression or unacceptable toxicity. Thromboprophylaxis was required. The most common grade 3/4 AEs were neutropenia (56.2%), anemia (32.3%), and thrombocytopenia (25.8%), which occurred within the first few cycles of treatment. Grade 3/4 infections occurred in 33.7% patients, of whom 13.9% had pneumonia, and 40.3% had neutropenia. Pomalidomide dose reductions or interruptions were reported in 24.2% and 66.0% of patients, respectively. AEs were managed by dose modifications and/or supportive care. Pomalidomide plus low-dose d...Continue Reading

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Dec 13, 2003·The Hematology Journal : the Official Journal of the European Haematology Association·Brian G M DurieUNKNOWN Scientific Advisors of the International Myeloma Foundation
Sep 23, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marcio Nucci, Elias Anaissie
Jan 15, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboRobert Z Orlowski
Oct 1, 2014·Expert Review of Hematology·Guillemette FouquetXavier Leleu
Oct 26, 2014·Haematologica·Cecilie BlimarkSigurdur Y Kristinsson
Apr 4, 2015·Blood·Ajay K NookaSagar Lonial
Jul 28, 2015·American Journal of Hematology·Wilson I GonsalvesLuciano J Costa
Oct 4, 2015·Haematologica·Evangelos TerposUNKNOWN European Myeloma Network
Jun 11, 2016·Future Oncology·Cyrille Touzeau, Philippe Moreau
Aug 2, 2016·Haematologica·Pieter Sonneveld, Annemiek Broijl
Aug 20, 2016·OncoTargets and Therapy·Nishitha ThumallapallyTerenig Terjanian

❮ Previous
Next ❯

Citations

Mar 7, 2018·Current Treatment Options in Cardiovascular Medicine·Dae Hyun Lee, Michael G Fradley
Feb 3, 2018·European Journal of Haematology·Pauline GueneauMathieu Boulin
Nov 5, 2019·Expert Review of Anticancer Therapy·Evangelos Eleutherakis-PapaiakovouMeletios A Dimopoulos
Jan 27, 2019·Molecular and Clinical Oncology·Eiseki UsamiTomoaki Yoshimura
Nov 8, 2020·European Journal of Cancer Care·Amélie CransacMathieu Boulin
Mar 7, 2020·Best Practice & Research. Clinical Haematology·Kylee MaclachlanDickran Kazandjian
Jul 5, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Haisam AbidMuhammad Bilal Abid
Sep 24, 2019·JACC. CardioOncology·Ronald M Witteles, Michaela Liedtke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.